Alzheimer disease-related presenilin-1 variants exert distinct effects on monoamine oxidase-A activity in vitro

Journal of Neural Transmission

Volumn 118, Issue 7, 2011, Pages 987-995

  Pennington, Paul R ^a   Wei, Zelan ^a   Rui, Lewei ^a   Doig, Jennifer A ^a   Graham, Brett ^a   Kuski, Kelly ^a   Gabriel, Geraldine G ^a   Mousseau, Darrell D ^a  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

Alzheimer disease; Monoamine oxidase; Neuron; Oxidative stress; Presenilin; Secretase

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; CLORGYLINE; GAMMA SECRETASE; GAMMA SECRETASE INHIBITOR; N [N (3,5 DIFLUOROPHENACETYL)ALANYL]PHENYLGLYCINE TERT BUTYL ESTER; PRESENILIN 1; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL CELL; BRAIN CELL; CATALYSIS; CELL STRAIN HEK293; CELL VIABILITY; CONFERENCE PAPER; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; HIPPOCAMPUS; HUMAN; HUMAN CELL; IMMUNODETECTION; IMMUNOPRECIPITATION; IN VITRO STUDY; MONOAMINERGIC SYSTEM; MOUSE; NEUROBLASTOMA CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN VARIANT; WILD TYPE;

ALZHEIMER DISEASE; ANIMALS; CELL LINE, TRANSFORMED; CELL LINE, TUMOR; DEPRESSIVE DISORDER; GENETIC VARIATION; HEK293 CELLS; HUMANS; MICE; MONOAMINE OXIDASE; NEUROBLASTOMA; NEURONS; PRESENILIN-1;

EID: 80051665108     PISSN: 03009564     EISSN: 14351463     Source Type: Journal    
DOI: 10.1007/s00702-011-0616-7     Document Type: Conference Paper

References (60)

1. Agbayewa MO (1986) Earlier psychiatric morbidity in patients with Alzheimer's disease. J Am Geriatr Soc 34:561-564 (Pubitemid 16100005)
2. Ankarcrona M, Hultenby K (2002) Presenilin-1 is located in rat mitochondria. Biochem Biophys Res Commun 295:766-770 (Pubitemid 34756914)
3. Arai H et al (1984) Changes of biogenic amines and their metabolites in postmortem brains from patients with Alzheimer-type dementia. J Neurochem 43:388-393 (Pubitemid 14093566)
4. Berger AK et al (1999) The occurrence of depressive symptoms in the preclinical phase of AD: a population-based study. Neurology 53:1998-2002
5. Burke WJ et al (2004) Neurotoxicity of MAO metabolites of catecholamine neurotransmitters: role in neurodegenerative diseases. Neurotoxicology 25:101-115 (Pubitemid 38044173)
6. Cao X et al (2007) Calcium-sensitive regulation of monoamine oxidase-A contributes to the production of peroxyradicals in hippocampal cultures: implications for Alzheimer diseaserelated pathology. BMC Neurosci 8:73
7. Cao X et al (2009a) Calcium alters monoamine oxidase-A parameters in human cerebellar and rat glial C6 cell extracts: possible influence by distinct signalling pathways. Life Sci 85:262-268
8. Cao X et al (2009b) Serine 209 resides within a putative p38 (MAPK) consensus motif and regulates monoamine oxidase-A activity. J Neurochem 111:101-110
9. Capell A et al (2000) Presenilin-1 differentially facilitates endoproteolysis of the beta-amyloid precursor protein and Notch. Nat Cell Biol 2:205-211
10. Caraci F et al (2010) Depression and Alzheimer's disease: neurobiological links and common pharmacological targets. Eur J Pharmacol 626:64-71
11. Chan-Palay V (1992) Depression and senile dementia of the Alzheimer type: a role for moclobemide. Psychopharmacology (Berl) 106(Suppl):S137-S139
12. Chan-Palay V et al (1993) Calbindin D-28k and monoamine oxidase A immunoreactive neurons in the nucleus basalis of Meynert in senile dementia of the Alzheimer type and Parkinson's disease. Dementia 4:1-15 (Pubitemid 23071252)
13. Curcio CA, Kemper T (1984) Nucleus raphe dorsalis in dementia of the Alzheimer type: neurofibrillary changes and neuronal packing density. J Neuropathol Exp Neurol 43:359-368 (Pubitemid 14089416)
14. Doan A et al (1996) Protein topology of presenilin 1. Neuron 17:1023-1030 (Pubitemid 26424028)
15. Geerlings MI et al (2008) History of depression, depressive symptoms, and medial temporal lobe atrophy and the risk of Alzheimer disease. Neurology 70:1258-1264 (Pubitemid 351520949)
16. Grudzien A et al (2007) Locus coeruleus neurofibrillary degeneration in aging, mild cognitive impairment and early Alzheimer's disease. Neurobiol Aging 28:327-335 (Pubitemid 46178530)
17. Grunblatt E et al (2005) Oxidative stress related markers in the "VITA" and the centenarian projects. Neurobiol Aging 26:429-438 (Pubitemid 40093926)
18. Guo Q et al (1999) Increased vulnerability of hippocampal neurons to excitotoxic necrosis in presenilin-1 mutant knock-in mice. Nat Med 5:101-106 (Pubitemid 29051006)
19. Hansson CA et al (2004) Nicastrin, presenilin, APH-1, and PEN-2 form active gamma-secretase complexes in mitochondria. J Biol Chem 279:51654-51660 (Pubitemid 40017916)
20. Hebert SS et al (2003a) Oligomerization of human presenilin-1 fragments. FEBS Lett 550:30-34 (Pubitemid 37281352)
21. Hebert SS et al (2003b) Dimerization of presenilin-1 in vivo: suggestion of novel regulatory mechanisms leading to higher order complexes. Biochem Biophys Res Commun 301:119-126 (Pubitemid 36268857)
22. Ishii T (1966) Distribution of Alzheimer's neurofibrillary changes in the brain stem and hypothalamus of senile dementia. Acta Neuropathol 6:181-187
23. Kang DE et al (2005) Presenilins mediate phosphatidylinositol 3-kinase/AKT and ERK activation via select signaling receptors. Selectivity of PS2 in platelet-derived growth factor signaling. J Biol Chem 280:31537-31547 (Pubitemid 41291897)
24. Kennedy BP et al (2003) Early and persistent alterations in prefrontal cortex MAO A and B in Alzheimer's disease. J Neural Transm 110:789-801 (Pubitemid 36783232)
25. Kessing LV, Andersen PK (2004) Does the risk of developing dementia increase with the number of episodes in patients with depressive disorder and in patients with bipolar disorder? J Neurol Neurosurg Psychiatry 75:1662-1666 (Pubitemid 39611460)
26. Kessing LV et al (2009) Antidepressants and dementia. J Affect Disord 117:24-29
27. Kosenko EA et al (2003) Calcium and ammonia stimulate monoamine oxidase A activity in brain mitochondria. Biol Bull Russ Acad Sci 30:449-452 (Pubitemid 37292640)
28. Lin MT, Beal MF (2006) Alzheimer's APP mangles mitochondria. Nat Med 12:1241-1243 (Pubitemid 44706922)
29. Liu Y et al (2008) Amyloid pathology is associated with progressive monoaminergic neurodegeneration in a transgenic mouse model of Alzheimer's disease. J Neurosci 28:13805-13814
30. Manczak M et al (2006) Mitochondria are a direct site of A beta accumulation in Alzheimer's disease neurons: implications for free radical generation and oxidative damage in disease progression. Hum Mol Genet 15:1437-1449
31. Marcyniuk B et al (1986) Loss of nerve cells from locus coeruleus in Alzheimer's disease is topographically arranged. Neurosci Lett 64:247-252 (Pubitemid 16163819)
32. Mejia S et al (2003) Nongenetic factors as modifiers of the age of onset of familial Alzheimer's disease. Int Psychogeriatr 15:337-349 (Pubitemid 38186253)
33. Meyer JH et al (2006) Elevated monoamine oxidase a levels in the brain: an explanation for the monoamine imbalance of major depression. Arch Gen Psychiatry 63:1209-1216 (Pubitemid 44708079)
34. Morohashi Y et al (2006) C-terminal fragment of presenilin is the molecular target of a dipeptidic gamma-secretase-specific inhibitor DAPT (N-[N-(3, 5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester). J Biol Chem 281:14670-14676 (Pubitemid 43855171)
35. Nishimura AL et al (2005) Monoamine oxidase a polymorphism in Brazilian patients: risk factor for late-onset Alzheimer's disease? J Mol Neurosci 27:213-217 (Pubitemid 41356402)
36. Parvizi J et al (2001) The selective vulnerability of brainstem nuclei to Alzheimer's disease. Ann Neurol 49:53-66 (Pubitemid 32163006)
37. Pugh PL et al (2007) Non-cognitive behaviours in an APP/PS1 transgenic model of Alzheimer's disease. Behav Brain Res 178:18-28
38. Reddy PH et al (2010) Amyloid-beta and mitochondria in aging and Alzheimer's disease: implications for synaptic damage and cognitive decline. J Alzheimers Dis 20(Suppl 2):S499-S512
39. Ringman JM et al (2004) Female preclinical presenilin-1 mutation carriers unaware of their genetic status have higher levels of depression than their non-mutation carrying kin. J Neurol Neurosurg Psychiatry 75:500-502 (Pubitemid 38338790)
40. Roychaudhuri R et al (2009) Amyloid beta-protein assembly and Alzheimer disease. J Biol Chem 284:4749-4753
41. Rub U et al (2000) The evolution of Alzheimer's disease-related cytoskeletal pathology in the human raphe nuclei. Neuropathol Appl Neurobiol 26:553-567 (Pubitemid 32049855)
42. Sastre M et al (2001) Presenilin-dependent gamma-secretase processing of beta-amyloid precursor protein at a site corresponding to the S3 cleavage of Notch. EMBO Rep 2:835-841 (Pubitemid 32982753)
43. Saura J et al (1994) Increased monoamine oxidase B activity in plaque-associated astrocytes of Alzheimer brains revealed by quantitative enzyme radioautography. Neuroscience 62:15-30 (Pubitemid 24287342)
44. Schneider I et al (2001) Mutant presenilins disturb neuronal calcium homeostasis in the brain of transgenic mice, decreasing the threshold for excitotoxicity and facilitating long-term potentiation. J Biol Chem 276:11539-11544
45. Shalat SL et al (1987) Risk factors for Alzheimer's disease: a casecontrol study. Neurology 37:1630-1633 (Pubitemid 17163587)
46. Shen J, Kelleher RJ 3rd (2007) The presenilin hypothesis of Alzheimer's disease: evidence for a loss-of-function pathogenic mechanism. Proc Natl Acad Sci USA 104:403-409 (Pubitemid 46123039)
47. Sherif F et al (1992) Brain gamma-aminobutyrate aminotransferase (GABA-T) and monoamine oxidase (MAO) in patients with Alzheimer's disease. J Neural Transm Park Dis Dement Sect 4:227-240
48. Smith IF et al (2002) Ca (2+) stores and capacitative Ca (2+) entry in human neuroblastoma (SH-SY5Y) cells expressing a familial Alzheimer's disease presenilin-1 mutation. Brain Res 949:105-111 (Pubitemid 35246182)
49. Szapacs ME et al (2004) Late onset loss of hippocampal 5-HT and NE is accompanied by increases in BDNF protein expression in mice co-expressing mutant APP and PS1. Neurobiol Dis 16:572-580 (Pubitemid 38942990)
50. Takehashi M et al (2002) Association of monoamine oxidase A gene polymorphism with Alzheimer's disease and Lewy body variant. Neurosci Lett 327:79-82 (Pubitemid 34722412)
51. Thinakaran G, Sisodia SS (2006) Presenilins and Alzheimer disease: the calcium conspiracy. Nat Neurosci 9:1354-1355 (Pubitemid 44646201)
52. Thinakaran G et al (1996) Endoproteolysis of presenilin 1 and accumulation of processed derivatives in vivo. Neuron 17:181-190 (Pubitemid 26251602)
53. Thinakaran G et al (1997) Evidence that levels of presenilins (PS1 and PS2) are coordinately regulated by competition for limiting cellular factors. J Biol Chem 272:28415-28422 (Pubitemid 27517788)
54. Thorpe L, Groulx B (2001) Depressive syndromes in dementia. Can J Neurol Sci 28(Suppl 1):S83-S95
55. Wei Z et al (2009) Haloperidol disrupts Akt signalling to reveal a phosphorylation-dependent regulation of pro-apoptotic Bcl-XS function. Cell Signal 21:161-168
56. Wiedemann N et al (2009) Connecting organelles. Science 325:403-404
57. Wu YH et al (2007) A promoter polymorphism in the monoamine oxidase A gene is associated with the pineal MAOA activity in Alzheimer's disease patients. Brain Res 1167:13-19
58. Wuwongse S et al (2010) The putative neurodegenerative links between depression and Alzheimer's disease. Prog Neurobiol 91:362-375
59. Yankner BA, Lu T (2009) Amyloid beta-protein toxicity and the pathogenesis of Alzheimer disease. J Biol Chem 284:4755-4759
60. Zweig RM et al (1988) The neuropathology of aminergic nuclei in Alzheimer's disease. Ann Neurol 24:233-242